[go: up one dir, main page]

AR054260A1 - Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos - Google Patents

Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Info

Publication number
AR054260A1
AR054260A1 ARP060101649A AR054260A1 AR 054260 A1 AR054260 A1 AR 054260A1 AR P060101649 A ARP060101649 A AR P060101649A AR 054260 A1 AR054260 A1 AR 054260A1
Authority
AR
Argentina
Prior art keywords
lower motor
methods
diseases
treatment
same
Prior art date
Application number
Other languages
English (en)
Inventor
Lucia Tabares
Arnon Rosenthal
John C Lin
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of AR054260A1 publication Critical patent/AR054260A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para el tratamiento, prevencion y/o disminucion de los síntomas relacionados con enfermedades de la neurona motora inferior (tales como la atrofia muscular espinal). Los métodos comprenden la administracion de un agonista de un anticuerpo anti-trkC. También se proveen composiciones y conjuntos de elementos (kits). Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende un anticuerpo agonista anti-trkC y un vehículo aceptable para el uso farmacéutico para tratar una enfermedad de las neuronas motoras inferiores en un individuo.
ARP060101649 2005-04-26 2006-04-25 Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos AR054260A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67539305P 2005-04-26 2005-04-26

Publications (1)

Publication Number Publication Date
AR054260A1 true AR054260A1 (es) 2007-06-13

Family

ID=37215513

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101649 AR054260A1 (es) 2005-04-26 2006-04-25 Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Country Status (7)

Country Link
US (1) US20070031418A1 (es)
EP (1) EP1877445A2 (es)
JP (1) JP2008539266A (es)
AR (1) AR054260A1 (es)
CA (1) CA2606196A1 (es)
TW (1) TW200716172A (es)
WO (1) WO2006116609A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327655D1 (de) * 2002-12-23 2009-06-25 Rinat Neuroscience Corp Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
US7848797B2 (en) * 2006-08-17 2010-12-07 Neurometrix, Inc. Motor unit number estimation (MUNE) for the assessment of neuromuscular function
EP2205071B1 (en) * 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US9597507B2 (en) 2014-10-31 2017-03-21 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN114424286A (zh) * 2019-09-30 2022-04-29 豪夫迈·罗氏有限公司 用于评定脊髓性肌萎缩 (sma) 的工具和方法
EP4370679A4 (en) * 2021-07-16 2025-11-12 Harvard College ACTIVATORS DIRECTING THE EXPRESSION OF MOTOR NEURONS

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) * 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (de) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
DK0730740T3 (da) * 1993-11-23 1998-09-28 Genentech Inc Kinasereceptoraktiveringsassay
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU721942B2 (en) * 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
AU2001271422B2 (en) * 2000-06-22 2005-12-22 Genentech, Inc. Agonist anti-trk-C monoclonal antibodies
AU2001286930A1 (en) * 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
DE60327655D1 (de) * 2002-12-23 2009-06-25 Rinat Neuroscience Corp Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法

Also Published As

Publication number Publication date
US20070031418A1 (en) 2007-02-08
CA2606196A1 (en) 2006-11-02
WO2006116609A3 (en) 2007-05-18
WO2006116609A2 (en) 2006-11-02
EP1877445A2 (en) 2008-01-16
WO2006116609A8 (en) 2008-05-08
TW200716172A (en) 2007-05-01
JP2008539266A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
AR054260A1 (es) Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
CR9994A (es) Vacuna terapéutica
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
UY30956A1 (es) Imidazo- y triazolopirimidinas sustituidas
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
ECSP088807A (es) Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1)
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
GT200900173A (es) Dispersión sólida de un antagonista de neuroquinina
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
CL2007001178A1 (es) Compuestos fusionados derivados de tetrahidro[1,2,4]triazol[4,3-a]pirimidina, moduladores de receptores de glutamato metabotropicos (mglur5); compuestos intermediarios; composicion y combinacion farmaceutica que los comprende; y su uso en la preparacion de medicamentos para tratar enfermedades gastroesofagicas, la ansiedad y dolores.
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.

Legal Events

Date Code Title Description
FB Suspension of granting procedure